CBAK posts falling revenue and net losses as Hitrans growth offsets battery slowdown

CBAK Energy Technology, Inc. (NASDAQ: CBAT) - quick read on what's happening inside the company (Q2 / 6‑months ended June 30, 2025)

Snapshot: CBAK is facing a clear operational slowdown in its battery segment while its materials arm (Hitrans) is growing. The income statement shows shrinking revenue, compressed gross margins and a return to net losses. Liquidity and working‑capital pressures are material - management warns of substantial doubt about going concern and is pursuing more financing while continuing heavy capex to expand capacity.

Key facts & figures (as reported)
- Net revenues (Q2 2025): $40,524,333 (down 15% from $47,793,045 Q2 2024).
- Gross profit (Q2 2025): $4,462,409 vs $12,728,026 (Q2 2024).
- Operating result (Q2 2025): Operating loss $(3,528,576) vs operating income $5,947,480 (Q2 2024).
- Net result (Q2 2025): Net loss $(3,360,398) vs net income $6,023,185 (Q2 2024).
- EPS (basic & diluted, Q2 2025): $(0.03) vs $0.07 (Q2 2024).
- Six months revenue YTD 2025: $75,463,234 (down 29% vs $106,615,477).
- Six months net loss YTD 2025: $(5,411,380) vs net income $15,595,659 (2024).
- Cash & equivalents (balance sheet at 6/30/25): $5,679,756 (note: cash & restricted cash per cash flow statement = $21,452,222).
- Current assets / current liabilities (6/30/25): $143,447,915 / $199,414,338 → working capital deficit ≈ $56.0M (reported).
- Total assets / total equity (6/30/25): $333,094,266 / $115,844,139.
- Bank borrowings (6/30/25): $38,757,000 (short‑ and long‑term combined).
- Inventories (6/30/25): $37,443,143 (up from $22,851,027 at 12/31/24); inventory write‑downs six months YTD: $2,579,738.
- Capital expenditures (6 months 2025): $22,319,029 (capex and construction in progress rising; construction in progress = $71,635,858).
- Stock repurchase program (authorized 5/20/25): up to $20M; 1,087,981 shares repurchased through 6/30/25 at average $1.15 for total ≈ $1.2M.
- Shares issued/outstanding (6/30/25): issued 90,099,500; outstanding 88,867,313.
- Going concern: Company discloses "substantial doubt" due to accumulated deficit, working capital deficiency and short‑term maturities.

What's happening inside - the drivers
- Product mix shift: Battery (CBAT) segment revenues fell sharply - especially residential energy/UPS batteries (Q2 2025: $18,521,374 vs $33,573,365 Q2 2024) - because of a planned product upgrade (26650 → 40135) that reduced utilization and sales timing. Hitrans (materials/cathode) is growing and narrowed the revenue gap: Q2 2025 Hitrans revenue $19,434,196 vs $12,194,921 in Q2 2024.
- Capacity build while demand re‑shapes: Heavy capex and construction in progress for Dalian, Nanjing, Zhejiang and Anhui plants (CIP rose to $71.6M). That increases depreciation/capital needs while the legacy product line sells less during transition.
- Cash flow squeeze: Operating cash flow weakened: net cash from operations YTD $4.15M vs $10.39M prior year; investing cash used $20.6M and financing cash used $24.6M - net effect = large cash outflow and reliance on borrowings and deposits.
- Balance‑sheet collateralization: Significant term deposits and pledged deposits secure acceptance bills and bank facilities (term deposits $40,054,842; pledged deposits $15,772,466) - some liquidity is tied up as collateral.

Income statement - positives
- Diversification in materials: Hitrans (cathode/precursor) revenues increased materially - cathode sales Q2 2025: $17,292,867 (up from $8,248,245). That provides higher‑margin product exposure as battery cell volumes retool.
- Cost control in some areas: Sales & marketing decreased (Q2 2025 $950,777 vs $1,368,373) and G&A has been broadly stable, limiting expense creep while revenue rotated between segments.
- Other income & government support: Government grants and other income provided some non‑operating support (other income, net Q2 2025: $352,951).

Income statement - negatives (material)
- Falling top line & margins: Revenue down 15% (Q2) and 29% (YTD) with gross margin collapsing (Q2 gross margin 11.0% vs 26.6% prior year; YTD gross margin 12.3% vs 29.5%).
- Return to operating losses: Operating loss Q2 $(3.53M) and YTD $(6.39M) versus strong profits the prior year - a rapid profit reversal.
- Inventory risk & write‑downs: Inventories up sharply (+$14.6M vs 12/31/24) and write‑downs remain material (Q2 write‑down $1.65M; YTD $2.58M), reflecting product transitions and slower sales.
- Tax and valuation headwinds: Large deferred tax valuation allowances remain; effective tax benefit in 2025 is nil despite losses because of limited realizability of NOLs for subsidiaries.
- Dilution / financing risk: Management plans additional bank and equity financing; failure to secure acceptable financing would magnify going‑concern risk.

Near‑term risks and catalysts to watch
- Demand recovery for upgraded battery models: Successful ramp of Model 40135 (and other new cells) - improves utilization and margins.
- Hitrans growth momentum: Continued expansion in cathode sales and new customer wins - could offset battery weakness.
- Liquidity moves: Cash generation, drawdowns on committed facilities, or new equity issuance - any of these will materially change risk profile.
- Inventory turn and write‑downs: Lower future write‑downs and improved inventory turnover are essential to restore margins and operating cash flow.

One‑line conclusion
CBAK (NASDAQ: CBAT) is in a transitional phase: materials (Hitrans) is a real growth offset, but the legacy battery business is down while the company spends to upgrade and expand capacity. The income statement shows a clear deterioration - falling revenues, compressed gross margins and a shift back to losses - and the balance sheet/cash flow profile creates genuine near‑term financing risk. This is a classic execution / liquidity story: if management can stabilize sales and monetize the Hitrans growth while securing affordable funding, the company can recover; if not, the going‑concern and dilution risks will intensify.

Sources: CBAK Energy Technology, Inc. Form 10‑Q - Condensed consolidated financial statements and MD&A for the three and six months ended June 30, 2024 and 2025.